



November 12, 2014

GlycoMimetics to Present at Stifel Healthcare Conference 2014

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Stifel Healthcare Conference 2014 on Tuesday, November 18, 2014 at 3:00 p.m. Eastern Time. The conference will take place in New York City.

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. GlycoMimetics' lead drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease and will be studied in a Phase 3 clinical trial to be conducted by Pfizer Inc., the company's collaborator for rivipansel. GlycoMimetics' drug candidate GMI-1271, a novel and proprietary E-selectin antagonist, is being developed as a potential therapy for acute myeloid leukemia (AML) and other blood disorders and is being studied in a Phase 1 clinical trial. Learn more at www.glycomimetics.com.

GlycoMimetics
Brian Hahn, 240-243-1207
bhahn@glycomimetics.com

Source: GlycoMimetics, Inc.

News Provided by Acquire Media